Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapies

Irene Ghobrial • 29 Oct 2022
IWWM-11 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide Teclistamab Thalidomide

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, briefly highlights the recent FDA approval of teclistamab for relapsed/refractory (R/R) multiple myeloma, and the growing value of immunotherapies in this space. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Irene Ghobrial

0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
1:19
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial • 11 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals